Why is the Pro Medicus share price sinking on Monday?

What's going on with shares in the medical imaging company today?

| More on:
a concerned medical doctor examines an Xray from an imaging machine in a hospital setting.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Pro Medicus shares are down 7.2% to $44.06
  • The company's share price is being heavily weighed down by Wall Street's performance on Friday
  • Trading at an extremely high P/E ratio, investors have chosen to sell off Pro Medicus shares

The Pro Medicus Ltd (ASX: PME) share price is plummeting today despite no new announcements from the company.

At the time of writing, the health imaging company's shares are down a sizeable 7.2% to $44.06 after recovering from an intraday low of $43.05. That's 9.3% lower.

What's dragging Pro Medicus shares lower?

A catalyst for the Pro Medicus share price falling deep in the red today has come from broader market weakness.

The S&P/ASX 200 Index (ASX: XJO) is tumbling 1.31% lower to 7,337 points following Wall Street's heavy losses last week.

In particular, the tech-focused Nasdaq fell 4.2% on Friday, registering its lowest closing levels in more than 12 months.

The selling pressure led to the index sinking 13.26% in April, its worst month since October 2008. This was brought on by an underwhelming performance from the tech titans such as Amazon, Netflix, and Meta Platforms.

While Pro Medicus is not directly related to the above companies, it does operate in the United States.

Furthermore, with an extremely high price-to-earnings (P/E) ratio of 118.95, this is bound to cause a jerk reaction.

Investors clearly are putting a lot of hope on Pro Medicus further expanding in North America. However, with the current market volatility, the company's shares are the first to be hit hard.

About the Pro Medicus share price

Over the last 12 months, the Pro Medicus share price has lost around 7% with year to date down 30%.

The company's shares reached a 2022 high of $63.12 on 4 January, before plunging 30% in the weeks following.

Since then, the company's shares have moved in circles.

Based on valuation grounds, Pro Medicus commands a market capitalisation of around $4.6 billion.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Pro Medicus Ltd. The Motley Fool Australia has positions in and has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies
Opinions

Forget CSL shares, I'd buy this booming biotech stock instead

This ASX biotech stock has caught my eye this year.

Read more »

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.
Healthcare Shares

Telix Pharmaceuticals shares crash 58% from their peak: Buying opportunity or time to sell up?

The biopharmaceutical company's shares are tipped to soar next year.

Read more »

A male ASX investor sits cross-legged with a laptop computer in his lap with a slightly crazed, happy, excited look on his face while next to him a graphic of a rocket shoots upwards with graphics of stars scattered around it
Healthcare Shares

Up 10x since July, could this hot ASX stock be the next Droneshield?

Investors chase asymmetric upside and 4DMedical is one of the ASX's hottest stocks right now.

Read more »

A couple smile as they look at a pregnancy test.
Healthcare Shares

Is Medibank stock a buy for its 5.5% dividend yield?

This business is providing investors with very healthy dividends.

Read more »

A doctor shrugs and holds his hands out.
Healthcare Shares

Down 36% in 2025, should you buy CSL shares today?

A leading investment expert offers his outlook for CSL’s beaten-down share price.

Read more »

Three guys in shirts and ties give the thumbs down.
Healthcare Shares

Why did Macquarie just downgrade CSL shares?

The broker has taken an axe to its valuation of this biotech giant.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Which drug company could pile on almost 30% in gains according to RBC Capital?

This drug company has plenty of irons in the fire, RBC Capital Markets says.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

This ASX 200 stock is charging higher on FDA approval news

This stock is avoiding the market weakness on Monday. Let's find out why.

Read more »